Acadia Pharmaceuticals Inc. Canaccord Genuity's 46th Annual Growth Conference

I think we're ready to launch into these questions.

Great introduction. Thank you. Great.

Thanks for the question. Good afternoon, everyone. Starting with NUPLAZID, which is our treatment for Parkinson's disease psychosis, I think as you mentioned, we've seen very nice traction for that brand over the last 10 years. In fact, over the last few years, we've actually seen accelerated growth for it. Just in the last quarter alone, we saw 20% year-over-year growth in terms of new-to-brand prescriptions. I think what is underpinning that for NUPLAZID is two things. One, we've really been kind of leaning in heavily to educate people living with Parkinson's disease that actually hallucinations and delusions is part of the disease course, so we're trying to drive awareness that way.

At the same time, we've also been focused very much on ensuring that HCPs who see patients living with PDP are aware that when you see these patients, you should be treating them, and NUPLAZID is the first and only approved therapy for patients living with PDP. So I think a dual approach there. One is around education. The second is really around focusing the messaging, the segmentation, and our sales force effort on the right customer at the right time. As it relates to DAYBUE, which is our treatment for Rett syndrome, again, first and only approved treatment there. I think we've learnt a great deal about this marketplace since we've launched. This was a completely new treatment, completely new category in essence. Since we've launched, we've learnt to turn around not only the asset itself and its profile, but again, how we go about commercializing that.

Again, rare disease is somewhat unique. You have to really get down to N-of-1 as it relates to understanding the patient, but also thinking about the HCP who is part of that story. Again, there has been a significant amount of education required, both for the clinical community, but also for the patient community and the caregiver community. There has been a very strong advocacy play. Again, that is part of the playbook for rare disease. I think what is common across the two is a real steadfast focus on execution. We have to make sure that we execute appropriately, and that has been a focus certainly since I have been with the company for the last two years.

Mm-hmm. Well, I think if you think about Parkinson's disease, we estimate that there is 1 million people in the United States living with Parkinson's disease today, and we think that that number over time is actually going to grow. To your point, I think it is exciting that there are new players coming into the marketplace. As we think about the efforts that we have undertaken to really drive awareness, as I have mentioned, we understood certainly over the last few years that one of the issues that people with Parkinson's face is they understand the movement disorder side of things. But some of the other conditions that they face, psychosis being one, they are not particularly au fait with because they are just concentrating on the actual movement side of things.